ARQL Profile
ArQule, Inc. (ARQL) was a biopharmaceutical company focused on the discovery and development of small molecule drugs for the treatment of cancer and rare diseases. The company's product candidates were designed to target specific proteins and pathways involved in cancer cell growth and survival, as well as other diseases.
ArQule's lead product candidate was called tivantinib, which was in clinical development for the treatment of liver cancer and non-small cell lung cancer. The company also had a number of other product candidates in various stages of development for the treatment of other types of cancer, as well as fibrosis and inflammatory diseases.
ArQule was founded in 1993 and was headquartered in Burlington, Massachusetts. In 2019, the company was acquired by Merck & Co., Inc., a global pharmaceutical company, for $2.7 billion. As a result of the acquisition, ArQule is now a wholly owned subsidiary of Merck and is no longer a publicly traded company.
|
